Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Cidara Therapeutics (CDTX) Tops Q1 EPS by 9c
May 11, 2023 4:39 PM EDTCidara Therapeutics (NASDAQ: CDTX) reported Q1 EPS of $0.03, $0.09 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $25.99 million versus the consensus estimate of $16.25 million.
For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.
... More